Company Description

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.

It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.

Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Evoke Pharma, Inc.

Country	United States
Founded	2007
IPO Date	Sep 25, 2013
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	4
CEO	Matthew D'Onofrio

Contact Details

Address: 420 Stevens Avenue, Suite 230 Solana Beach, California 92075 United States
Phone	858 345 1494
Website	evokepharma.com

Stock Details

Ticker Symbol	EVOK
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001403708
CUSIP Number	30049G104
ISIN Number	US30049G2030
Employer ID	20-8447886
SIC Code	2834

Key Executives

Name	Position
Matthew J. D'Onofrio MBA	Co-Founder, Chief Executive Officer and Director
Dr. Marilyn R. Carlson D.M.D., M.D., RAC.	Chief Medical Officer
Mark A. Kowieski CPA	Chief Financial Officer
Christopher Quesenberry	Chief Commercial Officer - Gimoti (TM)

Latest SEC Filings

Date	Type	Title
Nov 22, 2024	424B5	Filing
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024	8-K	Current Report
Nov 7, 2024	10-Q	Quarterly Report
Nov 6, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership
Oct 29, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Oct 28, 2024	8-K	Current Report
Oct 22, 2024	8-K	Current Report
Oct 17, 2024	8-K	Current Report

View All SEC Filings